What's Happening?
Onchilles Pharma has presented new preclinical data from its NEU-002 program at the AACR Annual Meeting 2026. The program focuses on extending the ELANE pathway into systemic delivery, targeting solid tumors with a cancer-selective mechanism that spares
immune cells while activating anti-tumor immunity. Preclinical models demonstrated anti-tumor activity following intravenous and intraperitoneal administration, with two lead candidates advancing toward final development candidate selection. The NEU-002 program aims to protect elastase activity against circulating serine protease inhibitors, supporting its potential as a systemic approach for solid tumors.
Why It's Important?
The NEU-002 program represents a significant advancement in cancer treatment, offering a systemic approach that could address solid tumors not well served by local delivery methods. By leveraging the ELANE pathway, the program aims to provide a more effective and durable cancer treatment, potentially overcoming limitations of traditional chemotherapy and immunotherapy. This approach could lead to improved patient outcomes, offering a new therapeutic option for cancers with elevated histone H1 levels, regardless of genetic makeup or immune status.
What's Next?
Onchilles Pharma plans to continue evaluating the NEU-002 candidates, including non-human primate pharmacokinetic studies, to inform final development candidate selection. The company aims to advance these candidates toward clinical translation, potentially offering a new systemic treatment option for solid tumors. Further research will focus on optimizing the delivery and efficacy of the NEU-002 program, with the goal of achieving durable anti-tumor immunity and expanding its application to various cancer types.
